you could also say that someone at MDXH should every so often read the blurb on their website to keep it up to date and relevant!
."..PASCUAL Study is a 600 patient randomized, controlled prospective study to track the clinical utility of the ConfirmMDx assay in U.S. urologic practices for the management of patients with a previous histopathologically cancer-negative biopsy, but clinical risk factors suggesting the need for a repeat biopsy. The study, initiated in H2 2014, will compare the rate of repeat biopsies under the standard of care to the rate of repeat biopsies in patients managed with ConfirmMDx test results and is expected to demonstrate a similar low rate of repeat biopsy in the ConfirmMDx arm as reported by Wojno et al. The PASCUAL study, led by Principal Investigator Neal D. Shore, MD, FACS, CPI who serves as Medical Director for the Carolina Urologic Research Center, is expected to be completed in H1 2017.